Soleno Therapeutics : Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome Enrollment completion satisfies closing condition on December 2022 Securities Purchase Agreement and triggers $10 million capital infusion - Form 8-K

Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome


Enrollment completion satisfies closing... | May 3, 2023

Related Keywords

,Soleno Therapeutics Inc ,Foundation For Prader Willi Research ,Prader Willi Research ,Orphan Drug Designation ,Fast Track Designation ,Diazoxide Choline ,Soleno Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Data ,Xpected ,N ,3 ,023 ,End ,Gas ,The ,Potential ,O ,Support ,Fda ,Submission ,Or ,Ccr ,Trader ,Hilli ,Enrollment ,Completion ,Atisfies Slno Us8342033094 ,